Gene Therapy HTA: How Do The European, Australian And Canadian Systems Shape Up?
Executive Summary
A report comparing the health technology assessment methods used in nine European countries, Australia and Canada found that England has the most favorable reimbursement landscape for gene therapies – but outlined several areas for improvement across the board.
You may also be interested in...
Orchard On The Trials, Tribulations And Triumphs Of Gene Therapy HTA
Convincing payers to fund a $3m therapy is no mean feat, even for innovations with curative potential. Orchard Therapeutics, a company with much experience in this field, tells the Pink Sheet why it values open dialogues, and outlines how health technology assessment methods could be improved.
England: CSL Undeterred By Draft NICE Rejection Of Its £2.6m Hemophilia B Gene Therapy
CSL Behring said it remains confident that a market access agreement for its hemophilia B gene therapy Hemgenix can be reached after England’s HTA body NICE rejected the product because of uncertainties over its long-term benefit and cost-effectiveness.
Gene Therapy: Years After Accelerated Approval, Will US FDA Still Be Asking ‘Does It Work?’
Retiring Office of Tissues and Advanced Therapies’ Director Wilson Bryan expects the expedited pathway will be used more frequently moving forward, but worries that ambiguous confirmatory trial results many years down the line will still leave efficacy questions unanswered.